Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iridex (IRIX) Gains from Sales and Divestitures (2012 - 2015)

Iridex's quarterly Gains from Sales and Divestitures came in at $3503.0 in Q1 2015, down 67.16% year-on-year from $10666.0 in Q1 2014, and down 92.51% quarter-over-quarter from $46759.0 in Q3 2014.

Iridex has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $3503.0 in Q1 2015.

  • For the quarter ending Q1 2015, Gains from Sales and Divestitures fell 67.16% year-over-year to $3503.0; the trailing twelve-month figure through Jan 2015 stood at $3503.0 (down 67.16% YoY), and the FY2015 full-year result was $3503.0, down 67.16% from the prior year.
  • Gains from Sales and Divestitures for Q1 2015 stood at $3503.0, down from $46759.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $46759.0 in Q3 2014, with the low at -$10126.0 in Q3 2012.
  • Average Gains from Sales and Divestitures over 4 years is $14459.6, with a median of $10396.0 recorded in 2012.
  • Year-over-year, Gains from Sales and Divestitures soared 2800.0% in 2014 and sank 67.16% in 2015.
  • Tracing IRIX's Gains from Sales and Divestitures over 4 years: stood at $10126.0 in 2012, then gained by 5.33% to $10666.0 in 2013, then surged by 338.39% to $46759.0 in 2014, then plunged by 92.51% to $3503.0 in 2015.
  • The last three Gains from Sales and Divestitures figures came in at $3503.0 (Q1 2015), $46759.0 (Q3 2014), and $36250.0 (Q2 2014), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Iridex 18.87 Mn 14.27 Mn 4.74 Mn

Historic Data

Download Data 🔒
DateValue
Jan 3, 2015 3,503.00
Jan 3, 2015 3,503.00
Sep 27, 2014 46,759.00
Sep 27, 2014 46,759.00
Jun 28, 2014 36,250.00
Jun 28, 2014 36,250.00
Mar 29, 2014 35,000.00
Mar 29, 2014 35,000.00
Dec 28, 2013 10,666.00
Dec 28, 2013 10,666.00
Sep 28, 2013 17,249.00
Sep 28, 2013 17,249.00
Dec 29, 2012 15,189.00
Dec 29, 2012 15,189.00
Sep 29, 2012 -10,126.00
Sep 29, 2012 -10,126.00